Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome that is caused primarily by immune-mediated destruction of hematopoietic stem cells. Traditional treatment relies on immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CSA). However, the...
Saved in:
| Main Authors: | Yuting Dai, Qiang Guo, Xiaoxiao Guo, Qiuju Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1609771/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study
by: Yuan Yang, et al.
Published: (2024-12-01) -
Cost utility analysis of adult patients with severe aplastic anemia: a single-center study
by: Lin Chen, et al.
Published: (2025-12-01) -
Disseminated Histoplasmosis in a Patient with Aplastic Anemia
by: Sanjeev Kumar Sharma, et al.
Published: (2014-08-01) -
Clinical case of COVID-19 course in a child with aplastic anemia
by: D. O. Ivanov, et al.
Published: (2022-04-01) -
TIM3 and TIGIT-expressing CD4 T cells are impacted by kidney transplantation and associated with risk of infection
by: Harry Pickering, et al.
Published: (2025-05-01)